



Operating Performance



FY 23/24 Performance





265.4 bn Shs

FY22/23: Shs 221.5 bn



Gross Profit

102.9 bn Shs

FY22/23: Shs 67.0 bn



■ EBITDA

53.7 bn Shs

FY22/23: Shs 38.7 bn



Profit after Tax

31.8 bn Shs

FY22/23: Shs 19.0 bn



Delivering growth, Creating value





SUSTAINABLE GROWTH:

- Market access: Replicate our Uganda business model in other countries
- Customer base penetration: Grow the current customer base through differentiated products of consistent quality
- Build private market segment in the region

COST LEADERSHIP:

Continue to focus on optimising operational cost and material margin

PORTFOLIO DEVELOPMENT:

- Using selective R&D, build a portfolio of products which will drive growth
- Licensing
- Add technology partnerships

BALANCED INVESTMENT:

 Direct future investments towards new products and capacity to create access to treatment for other diseases

Sustainability



IN ENVIRONMENTAL SUSTAINABILITY, WE FOCUS ON FOUR AREAS:



In respect of Scope 1 emissions, we are aspiring to achieve carbon neutrality by 2030



Water consumption:

We are aiming to reduce the consumption of blue water and aspiring to achieve water neutrality by 2028



Land pollution:

We are focused on reducing waste generated by our operations which goes to landfill and aspiring to achieve zero waste-tolandfill by 2025



Wastewater treatment:

We are applying safe discharge targets established by the antimicrobial resistance industry (AMR)

Social

- Zero fatalities
- **34**% Female representation at the senior management level
- 25% Of staff are female, influenced by the nature of our business activities
- 578 people seen by medical experts at the World Malaria Day medical camp
- Over 150 mosquito nets handed out in the community



Environment

- 70% Reduction in waste to landfill, above our target of 25%
- 11% Reduction in blue water utilised
- 1,305.2 KL Increase in other sources of water (rainwater, borehole and reverse osmosis)
- 100% Compliance with health and safety requirements; no legal notices or citations

Journey of Progress and Growth





Our journey began with a

JV with Cipla





manufactured product













CiplaQCi

Quality Chemical Industries Limited




- Technology License Agreement
 - Access to products
 - Waiver of \$1.6 million licensing fees
- 2 Transitional Service Agreement
- Manufacturing and Supply Agreement

Focused on Building a Strong Pipeline



Products













Pipeline

- ☐ 7 products under registration; In categories of anti-infectives, respiratory tract infections, and metabolic health. To be launched in Q3 of FY24/25
- □ 2 new products are in the pipeline for local manufacturing. Expected launch in Q4 of FY24/25



Impact of your Company





















Financial Performance



Financial Summary





Summary of Performance



(UGX billion)

Income Statement	FY2024	FY2023	Change %
Revenue	265.3	221.5	20%
Cost of Sales	162.4	154.5	5%
Gross Profit	102.9	67.0	54%
General and Administrative Expenses	59.8	69.7	-14%
EBITDA	53.7	38.8	39%
Profit after Tax	31.8	19.0	67%
Earnings per Share (UGX)	8.7	5.2	67%
Gross Dividend	20.8	9.1	128%
Dividend per Share (UGX)	5.7	2.5	128%
Financial Position at	31 March 2024	31 March 2024	Change %
Total Assets	232.0	213.5	9%
Shareholders' Equity	188.2	171.4	10%
Term Loan	0.0	5.4	-100%
Net Cash Generated from Operating Activities	67.1	41.8	60%

- Revenue increased by 20%, mainly attributed to increased orders in the export segment.
- Orders from GoU increased by 5%.
- The gross profit margin increased from 30% in FY22/23 to 39% in FY23/24, driven mainly by:
 - enhanced manufacturing efficiencies; and
 - · reductions in raw material costs.


This was partially offset by changes in product mix.


- The increase in general and administrative expenses is due to increased operations and inflationary headwinds.
- EBITDA increased by 39%, due to higher revenues, a higher gross margin, cost management and economies of scale.
- o PAT of UGX31.8 billion is the highest in Qcil's history.
- o Term loan settled.
- Proposed dividend payout growth of 185%, including first interim dividend paid in Qcil's history.
- Cash flows from operations increased by 61%, primarily due to strong operating performance and improved cash collections.


Historical Financial Performance



(bn Shs)










Cashflow



(bn Shs)





Financial Ratios



FY 24	FY 23		
18%	11%		
3.8	3.5	Robust cash flows, driven by strong	
124	101	operating performance, enabling enhanced	
		shareholder distributions	
8.7	5.2		
5.7	2.5		
	18% 3.8 124 8.7	18% 11% 3.8 3.5 124 101 8.7 5.2	

